Genscript Biotech (STU:G51) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:G51 Genscript Biotech Corp STU:G51
67 GF Score
Price €1.42
GF Value €2.25
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Genscript Biotech Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Genscript Biotech Valuation Rank Related Terms

STU:G51
67GF Score
Genscript Biotech Corp STU:G51
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Genscript Biotech (STU:G51) Overvalued in 2026?

Based on GuruFocus' analysis, Genscript Biotech stock appears to be undervalued. The current stock price of €1.42 is trading 36.9% below its estimated GF Value™ of €2.25. GuruFocus considers Genscript Biotech to be Significantly Undervalued.

Key valuation signals for STU:G51:

  • Valuation Rank:
  • GF Value™: €2.25 vs. price of €1.42 (36.9% below fair value)
  • GF Score™: 67/100 with 4 warning signs

No single metric tells the full story. See the STU:G51 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genscript Biotech Business Description

Other Exchanges GNNSF:USA01548:Hong Kong
Address 860 Centennial Avenue, Piscataway, NJ, USA, 08854
GenScript Biotech Corp is an investment holding company engaged in the manufacture and sale of life science research products and services, including life science services and products, biologics development services, and industrial synthetic biology products. Its segments include life science services and products, which generate maximum revenue and provide research services and products; biologics development services, which support the development of therapeutic antibodies and CGT products; industrial synthetic biology, which provides enzyme development and production using engineered microbial strains; and the operation unit, which provides shared services. It operates in Mainland China, which generates maximum revenue, U.S., Europe, and the Asia Pacific excluding Mainland China.
67GF Score

Get the complete analysis for STU:G51

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.42
Price
€2.25
GF Value